Metabolic TestingNCT07870434
The Metabolic Response of Unweighted Treadmill Walking
A study testing AlterG Treadmill and Metabolic Assessment in people with Metabolic Testing, run by NYU Langone Health at 2 sites in United States.
Trial summary
This study will use an experimental quantitative research design. Participants will serve as their own control with a metabolic assessment by open circuit spirometry when walking on the Alter G treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Testing
- What is being tested?
- AlterG Treadmill and Metabolic Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 2 sitesUnited States
- Study dates
- 6 Jan 2026to 13 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Apparently healthy college-age individuals
- Able to walk at a moderate pace (3 mph)
Who cannot join
None listed.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
NYU Langone Health
East Meadow, New York, 11554
Adelphi University
Garden City, New York, 11530
About this study
Official title: Establishing a Physiologic Baseline: Metabolic and Cardiovascular Responses to Graded Body-Weight Support During Anti-Gravity Treadmill Walking: A Repeated-Measures Crossover Study
This study will use an experimental quantitative research design. Participants will serve as their own control with a metabolic assessment by open circuit spirometry when walking on the Alter G treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. Randomly assigned trials at 25%, 50%, 75% and 100% of body mass will be conducted under steady state conditions. All trials will be conducted in one session.
- Conditions
- Metabolic Testing
- Being tested
- AlterG Treadmill, Metabolic Assessment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AlterG TreadmillOther
Participants will walk on an AlterG Treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. The randomly assigned trials will be completed at 25%, 50%, 75%, and 100% of body mass under steady-state conditions.
Metabolic AssessmentOther
Conducted using a Parvo Medics TrueOne 2400 metabolic cart and standard heart rate monitor, one way valve mouthpiece, and nose clip.
| Study group | Role | What they receive |
|---|---|---|
| Metabolic Assessment during AlterG Treadmill Use | Experimental | Each participant will undergo a metabolic assessment by open circuit spirometry (to be performed by the Adelphi study team) when walking on an AlterG Treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. The randomly assigned trials will be completed at 25%, 50%, 75%, and 100% of body mass under steady-state conditions. Receives: Other: AlterG Treadmill; Other: Metabolic Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oxygen Consumption at 25% Body Weight
Measured: Day 1
Oxygen Consumption at 50% Body Weight
Measured: Day 1
Oxygen Consumption at 75% Body Weight
Measured: Day 1
Oxygen Consumption at 100% Body Weight
Measured: Day 1
Heart Rate at 25% Body Weight
Measured: Day 1
Heart Rate at 50% Body Weight
Measured: Day 1
Heart Rate at 75% Body Weight
Measured: Day 1
Heart Rate at 100% Body Weight
Measured: Day 1
Ventilation at 25% Body Weight
Measured: Day 1
Ventilation at 50% Body Weight
Measured: Day 1
Ventilation at 75% Body Weight
Measured: Day 1
Ventilation at 100% Body Weight
Measured: Day 1
Carbon Dioxide Production at 25% Body Weight
Measured: Day 1
Carbon Dioxide Production at 50% Body Weight
Measured: Day 1
Carbon Dioxide Production at 75% Body Weight
Measured: Day 1
Carbon Dioxide Production at 100% Body Weight
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study start6 Jan 2026
- Primary completion13 Jan 2026
- Study completion13 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic TestingStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Collaborators
- Adelphi University
- Responsible party
- Sponsor
- Investigators
- Bob Otto, Principal investigator, Adelphi UniversityMark Grossman, MD, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07870434
- Sponsor's protocol ID
- 25-00004
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: mark.grossman@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing a Physiologic Baseline: Metabolic and Cardiovascular Responses to Graded Body-Weight Support During Anti-Gravity Treadmill Walking: A Repeated-Measures Crossover Study
- ClinicalTrials.gov ID
- NCT07870434
- Acronym / sponsor ID
- 25-00004
- Conditions
- Metabolic Testing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Collaborators
- Adelphi University
- Study start
- 6 Jan 2026 (actual)
- Primary completion
- 13 Jan 2026 (actual)
- Study completion
- 13 Jan 2026 (actual)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will use an experimental quantitative research design. Participants will serve as their own control with a metabolic assessment by open circuit spirometry when walking on the Alter G treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. Randomly assigned trials at 25%, 50%, 75% and 100% of body mass will be conducted under steady state conditions. All trials will be conducted in one session.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Metabolic Assessment during AlterG Treadmill Use | Experimental | Other: AlterG Treadmill, Other: Metabolic AssessmentEach participant will undergo a metabolic assessment by open circuit spirometry (to be performed by the Adelphi study team) when walking on an AlterG Treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. The randomly assigned trials will be completed at 25%, 50%, 75%, and 100% of body mass under steady-state conditions. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Apparently healthy college-age individuals
- Able to walk at a moderate pace (3 mph)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AlterG TreadmillParticipants will walk on an AlterG Treadmill for less than ten minutes per trial at 3 mph while supporting their entire body mass. The randomly assigned trials will be completed at 25%, 50%, 75%, and 100% of body mass under steady-state conditions. | Other | Metabolic Assessment during AlterG Treadmill Use |
| Metabolic AssessmentConducted using a Parvo Medics TrueOne 2400 metabolic cart and standard heart rate monitor, one way valve mouthpiece, and nose clip. | Other | Metabolic Assessment during AlterG Treadmill Use |
Primary outcome
Oxygen Consumption at 25% Body Weight
Time frame: Day 1
Oxygen Consumption at 50% Body Weight
Time frame: Day 1
Oxygen Consumption at 75% Body Weight
Time frame: Day 1
Oxygen Consumption at 100% Body Weight
Time frame: Day 1
Heart Rate at 25% Body Weight
Time frame: Day 1
Heart Rate at 50% Body Weight
Time frame: Day 1
Heart Rate at 75% Body Weight
Time frame: Day 1
Heart Rate at 100% Body Weight
Time frame: Day 1
Ventilation at 25% Body Weight
Time frame: Day 1
Ventilation at 50% Body Weight
Time frame: Day 1
Ventilation at 75% Body Weight
Time frame: Day 1
Ventilation at 100% Body Weight
Time frame: Day 1
Carbon Dioxide Production at 25% Body Weight
Time frame: Day 1
Carbon Dioxide Production at 50% Body Weight
Time frame: Day 1
Carbon Dioxide Production at 75% Body Weight
Time frame: Day 1
Carbon Dioxide Production at 100% Body Weight
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: Yes. The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: mark.grossman@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Related trials for Metabolic Testing
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Not yet recruitingPhase 1/2
A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations
Cochlear Synaptopathy
RecruitingObservational study
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Li-Fraumeni Syndrome, Neoplasms
RecruitingObservational study
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Active, not recruiting
Diabetes Toolkit at Discharge
Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bob Otto principal investigator
Adelphi University
Mark Grossman, MD principal investigator
NYU Langone Health
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AlterG Treadmill and Metabolic Assessment in people with Metabolic Testing, run by NYU Langone Health at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oxygen Consumption at 25% Body Weight (time frame: Day 1). The study lists 16 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.